Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decreased 50 percent or more in a sustained manner.

Patients enrolled in this cohort of the ongoing phase II clinical trial are individuals with relapsed CLL, all of whom had two or more earlier treatments followed by recurrent disease.

"Usually patients with highly resistant and refractory CLL would have progressed and possibly died by this time, but 82 percent remain on PCI-32765 and continue to improve." Byrd says.
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... with leading global lifestyle design firm kathy ireland® Worldwide for five additional years, ... Worldwide entered into an exclusive licensing agreement three years ago to design and ...
(Date:12/5/2016)... Louis, Missouri (PRWEB) , ... December 05, 2016 ... ... across ethnic, gender, and geographic lines. The goal of Castlewood Treatment Centers has ... disorder treatment accessible to as many people as possible. In that spirit, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Florida ... Florida Hospital West Florida Region. McGuinness brings experience in executive leadership and clinical ... physicians and leaders. , In her new role, that officially begins December 12, ...
(Date:12/5/2016)... ... 2016 , ... Sabah Shah MD, MBA has joined the Retina Group of New York ... founded by James M. Maisel, MD and has been providing tertiary medical and surgical retinal ... legacy of surpassing expectations amongst her peers. Growing up in a family of doctors, ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading ... with The American College of Surgeons (ACS) to provide basic bleeding control instructor ... Control Basic” course is a pilot program that fulfills the intent of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... a Phase 2 clinical study of sotagliflozin, a dual ... with JDRF, the leading global organization funding type 1 ... 2 clinical trial, which randomized a total of 87 ... 400 mg dose of sotagliflozin compared to a placebo ...
(Date:12/5/2016)... -- Sharn Anesthesia Inc. announced today that it has been ... Salter Labs.  The company also received the 2015 Salter ... sales performance. Salter Labs is a leading ... the market gold standard ECO 2 sampling cannulas. ... Parker Flex-Tip® Endotracheal Tube, which is a leading patient ...
(Date:12/5/2016)... , the first HIPAA compliant software collaboration platform for patients, physicians ... Styku, a California -based software and ... real-time 3D body scanning and analysis. Together with its other strategic ... feel their health like never before. ... , , "Bringing ...
Breaking Medicine Technology: